The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Astellas is experiencing strong global sales trends of XTANDI for prostate cancer and BETANIS/MYRBETRIQ/BETMIGA for overactive bladder.
Cyborg Score Rationale
The company has shifted back into profit on a trailing twelve month basis with net income of ¥322.9b compared to a loss of ¥57.4b a year ago, supported by three straight quarters of positive EPS in 2026. However, bears argue that revenue is forecast to decline about 5% per year over the next three years alongside a five year earnings decline rate of 6.6% a year.
Top Insights
Strong global sales momentum in flagship drugs XTANDI and BETANIS/MYRBETRIQ/BETMIGA driving upward forecast revisions
Trading on trailing P/E of 13.4x versus peer average of 19.5x and industry average of 16.5x, suggesting potential valuation discount
Divergence between recent strong quarterly revenue (¥505.8b-¥571.2b) and three-year forecasts predicting 5% annual decline creates key investment tension
Core oncology portfolio includes XTANDI, XOSPATA, PADCEV with expansion into adjacent therapeutic areas including ophthalmology and women's health
Named Competitors
Gilenya/Fingolimod — Immunology and rare disease focus
Pharmacovigilance — Oncology and diagnostics leader
Oncology Portfolio — Large cap diversified pharma
Specialty Pharma — Neurology and immunology specialist
Recent Developments
(February 2026) Announced upward revisions to consolidated financial forecast for FY2025 ending March 31, 2026
(Q3 2026) Posted revenue of ¥571.2 billion and basic EPS of ¥56.04